As of Friday close, PMV Pharmaceuticals Inc.’s (NASDAQ:PMVP) stock was down -$0.25, moving down -4.39 percent to $5.45. The average number of shares traded per day over the past five days has been 1,952,040 shares. 3 times new highs have been achieved over the past 5 days, with a $0.07 gain in that time frame. In the last twenty days, the average volume was 975,660, while in the previous 50 days, it was 687,592.
Since last month, PMVP stock retreated -27.53%. Shares of the company fell to $5.09 on 03/10/23, the lowest level in the past month. A 52-week high of $24.26 was reached on 01/04/23 after having rallying from a 52-week low of $5.09. Since the beginning of this year, PMVP’s stock price has dropped by -37.36% or -$3.25, and marked a new high 2 times. However, the stock has declined by -77.54% since its 52-week high.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
PMVP stock investors should be aware that PMV Pharmaceuticals Inc. (PMVP) stock had its last reported insider trading activity 296 days ago on May 26. ORBIMED ADVISORS LLC, the 10% Owner of the company, disposed of 26,253 shares for $15.93 on May 26. It resulted in a $418,210 divestment by the insider. ORBIMED ADVISORS LLC sold 34,500 shares at an average price of $21.17 on Mar 31. The insider now owns 0 shares following the transaction. On Mar 30, 10% Owner ORBIMED ADVISORS LLC sold 75,000 shares at $22.39 apiece. The transaction was valued at $1,679,250.
In the three months ended December 30, PMV Pharmaceuticals Inc.’s quick ratio stood at 22.80, while its current ratio was 22.80, showing that the company is able to pay off its debt. Based on annual data, PMVP earned $3.71 million in gross profit and brought in $77.04 million in revenue.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. While analysts expected PMV Pharmaceuticals Inc. to report -$0.44 quarterly earnings, the actual figure was -$0.43 per share, beating the consensus estimate by 2.30%. During the quarter, the company generated -$21.61 million in EBITDA. The liabilities of PMV Pharmaceuticals Inc. were 24.28 million at the end of its most recent quarter ended December 30, and its total debt was $13.98 million. The value of shareholders’ equity is $45.77 million.
This quick technical analysis looks at PMV Pharmaceuticals Inc.’s (PMVP) price momentum. With a historical volatility rate of 54.10%, the RSI 9-day stood at 30.35% on 17 March.
With respect to its five-day moving average, the current PMV Pharmaceuticals Inc. price is up by +1.30% percent or $0.07. At present, PMVP shares trade -28.10% below its 20-day simple moving average and -55.73% percent below its 100-day simple moving average. However, the stock is currently trading approximately -40.50% below its SMA50 and -53.66% below its SMA200.
Stochastic coefficient K was 19.70% and Stochastic coefficient D was 20.52%, while ATR was 0.45. Given the Stochastic reading of 14.88% for the 14-day period, the RSI (14) reading has been calculated as 30.87%. As of today, the MACD Oscillator reading stands at -0.06, while the 14-day reading stands at -0.26.
Oppenheimer upgraded its rating on PMV Pharmaceuticals Inc. (NASDAQ: PMVP) to an Outperform in a note to investors on March 02, 2022. The analysts firm previously had a Perform rating on the stock.PMV Pharmaceuticals Inc. (PMVP) has been rated Buy by analysts. According to 0 brokerage firms, PMVP is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate PMV Pharmaceuticals Inc. stock as buy, with 6 recommending it as overweight.
With a median target price of $18.00, the current consensus forecast for the stock is $15.00 – $25.00. Based on these forecasts, analysts predict PMV Pharmaceuticals Inc. (PMVP) will achieve an average price target of $19.20.